Goldman Sachs lowered its target price for Hua Medicine (02552) to HK$11.6 from HK$12.9 and maintained its "buy" rating.
The research house said Hua's 1H net loss was Rmb236mn. Its cash of Rmb1,246mn by 1H could cover company's operations in 2019/20, with Goldman's estimated R&D spending of Rmb347mn/Rmb426mn.
Goldman sees 4Q 2019/2Q 2020 as critical for Hua, with 24-week efficacy data on Dorzagliatin as monotherapy (estimated in 4Q 2019) and in combination with metformin (estimated in 2Q 2020) could potentially be released, which may lead to global collaborations and NDA filing.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
